Completed PHASE4 INTERVENTIONAL 3-arm NCT00684671

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Challenge Dose Administration of Twinrix™ or Comparator 4 Years After Primary Vaccination.

Sponsor: GlaxoSmithKline

Interventions Engerix-B HBVAXPRO Havrix Twinrix Vaqta

Updated 8 times since 2017 Last updated: Jul 2, 2018 Started: May 26, 2008 Primary completion: Nov 3, 2008 Completion: Nov 3, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00684671, this PHASE4 trial focuses on Hepatitis A and Hepatitis B and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hradec Králové, Czechia
• Wilrijk, Belgium